Eli Lilly reported fourth-quarter revenue of $19.3 billion, a 43% year-over-year increase, with adjusted earnings per share of $7.54, up 42%. The company guided for 2025 revenue between $80 billion and $83 billion, implying 25% growth at the midpoint, which exceeded analyst expectations despite price cuts on some key medicines. Lilly’s tirzepatide franchise, sold as Mounjaro and Zepbound, generated well over $30 billion in 2025 sales and captured a 60.5% share of the incretin analog market by year-end, compared to Novo Nordisk’s 39.1%. The company’s pipeline includes the oral GLP-1 candidate orforglipron, which could win approval by the second quarter of 2026, and the triple-hormone agonist retatrutide, which delivered strong phase 3 results.
Eli Lilly and CompanyEli Lilly's tirzepatide franchise captured 60.5% market share in incretin analogs, driving 43% revenue growth and strong guidance.
Novo Nordisk A/S